Long-term phenotypic correction of rodent hemiparkinsonism by gene therapy using genetically modified myoblasts

Gene Therapy

Volumn 7, Issue 5, 2000, Pages 445-449

  Cao, L ^a   Zhao, Y C ^c   Jiang, Z H ^b   Xu, D H ^a   Liu, Z G ^c   Chen, S D ^c   Liu, X Y ^a   Zheng, Z C ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Gene therapy; Myoblasts; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; MESSENGER RNA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; MYOBLAST; NONHUMAN; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA; RODENTIA;

EID: 0034101456     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301096     Document Type: Article

References (32)

1. Koller W et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Tremor Ann Neurol 1997; 42: 292-299.
2. Baron MS et al. Treatment of advanced Parkinson's disease by posterior Gpi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996; 40: 355-366.
3. Gage FH. Cell therapy. Nature 1998; 392 (Suppl.): 18-24.
4. Kordower JH, Freeman TB, Olanow CW. Neuropathology of fetal nigral grafts in patients with Parkinson's disease. Mov Disord 1998; 13 (Suppl. 1): 88-95.
5. Wolff JA et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1989; 86: 9011-9014.
6. Anton R et al. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp Neurol 1994; 127: 207-218.
7. Clarkson ED et al. Improvement of neurological deficits in 6-hydroxydopamine-lesioned rats after transplantation with allogeneic simian virus 40 large tumor antigen gene-induced immortalized dopamine cells. Proc Natl Acad Sci USA 1998; 95: 1265-1270.
8. Gage FH, Ray J, Fisher LJ. Isolation, characterisation, and use of stem cells from the CNS. Annu Rev Neurosci 1995; 18: 159-192.
9. Hoshimaru M, Ray J, Gage FH. Differentiation of immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene. Proc Natl Acad Sci USA 1996; 93: 1518-1523.
10. Sah DWY, Ray J, Gage FH. Bipotent progenitor cell lines from the human CNS. Nature Biotech 1997; 15: 574-580.
11. Hefti F, Melamed E, Sahakian BJ, Wurtman RJ. Circling behaviour in rats with partial, unilateral nigrostriatal lesions: effect of amphetamine, apomorphine, and dopa. Pharmacol Biochem Behav 1980; 12: 185-188.
12. Koller WC, Rueda MG. Mechanism of action of dopaminergic agents in Parkinson's disease. Neurol 1998; 50 (Suppl. 6): s11-s13.
13. Friedmann T, Gage FH. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1989; 86: 9011-9014.
14. Horrellou P, Marlier L, Privat A, Mallet J. Behavioural effect of engineered cells that synthesize L-dopa or dopamine after grafting into the rat neostriatum. Eur J Neurosci 1990; 2: 116-119.
15. Fisher LJ et al. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produced L-dopa. Neuron 1991; 6: 371-380.
16. Jiao S, Gurevich V, Wolff JA. Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 1993; 362: 450-453.
17. Retracted by Wolff JA Nature 1996; 380: 734.
18. Hohlfeld R, Engle AG, Goebels N, Behrens L. Cellular immune mechanisms in inflammatory myopathies. Curr Opin Rheumatol 1997; 6: 520-526.
19. Fiandaca MS, Bakay RA, Sweeney KM, Chan WC. Immunologic response to intracerebral fetal neural allografts in the rhesus monkey. Prog Brain Res 1988; 78: 287-296.
20. La Rosa FG, Talmage DW. Major histocompatibility complex antigen expression of parenchymal cells of thyroid allografts is not by itself sufficient to induce rejection. Transplantation 1990; 49: 605-609.
21. Chang PL, Shen N, Westcott AJ. Delivery of recombinant gene products with microencapsulated cells in vivo. Hum Gene Ther 1993; 4: 433-440.
22. Morrison SJ, Nirao MS, Anderson DJ. Regulatory mechanisms in stem cell biology. Cell 1997; 88: 287-298.
23. Mckay R. Stem cells in the central nervous system. Science 1997; 276: 66-71.
24. Cao L et al. Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Hum Gene Ther 1995; 6: 1497-1501.
25. Imaoka T, Date I, Ohmoto T, Nagatsu T. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex. Hum Gene Ther 1998; 9: 1093-1102.
26. During MJ et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Therapy 1998; 5: 820-827.
27. Horellou P et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 1994; 6: 49-53.
28. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
29. During MJ, Naegele JR, O'Malley KL, Geller AL. Long-term behaviour recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-1403.
30. Yaffe D. Retention of differentiation potentialities during prolonged cultivation of myogenic cells. Proc Natl Acad Sci USA 1968; 61: 477-483.
31. De La Torre JC. Standardization of the sucrose-potassium phosphate-glyoxylic acid histofluorescence method for tissue monoamines. Neurosci Lett 1980; 17: 339-340.
32. Petrondas DA, Gabriel RK. Multiple comparisons by rerandomization tests. J Am Stat Assoc 1983; 78: 949-957.